CAPTRUST Financial Advisors
PTGX icon

CAPTRUST Financial Advisors’s Protagonist Therapeutics PTGX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$799K Buy
6,522
+4,620
+243% +$483K ﹤0.01% 1862
2026
Q1 		$200K Sell
1,902
-830
-30% -$73.5K ﹤0.01% 2685
2025
Q4 		$239K Sell
2,732
-580
-18% -$47.5K ﹤0.01% 2411
2025
Q3 		$220K Buy
+3,312
New +$188K ﹤0.01% 2359
2025
Q1 		– Sell
-5,878
Closed -$227K – 2433
2024
Q4 		$227K Sell
5,878
-248
-4% -$10.8K ﹤0.01% 2084
2024
Q3 		$276K Sell
6,126
-14
-0.2% -$566 ﹤0.01% 1928
2024
Q2 		$213K Buy
+6,140
New +$180K ﹤0.01% 2004
2022
Q1 		– Sell
-1,153
Closed -$39K – 5090
2021
Q4 		$39K Buy
1,153
+1,110
+2,581% +$35.1K ﹤0.01% 2858
2021
Q3 		$1K Buy
+43
New +$1.83K ﹤0.01% 4471

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

CAPTRUST Financial Advisors's PTGX Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Protagonist Therapeutics (PTGX) stake by 243% in Q2 2026, buying an estimated $483K and bringing the position to 6,522 shares worth $799K. The position accounts for ﹤0.01% of the portfolio, ranked #1862.

CAPTRUST Financial Advisors first reported a position in PTGX in Q3 2021 and has held it in 9 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • CAPTRUST Financial Advisors held 6,522 shares of Protagonist Therapeutics worth $799K as of Q2 2026.
  • CAPTRUST Financial Advisors bought 4,620 Protagonist Therapeutics shares in Q2 2026, an estimated $483K.
  • Protagonist Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #1862 holding.
  • CAPTRUST Financial Advisors first reported a position in Protagonist Therapeutics in Q3 2021 and has held it in 9 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.